Acute Myeloid Leukemia Version 3.2022
Anal Carcinoma Version 1.2023
B-Cell Lymphomas Version 1.2023
Breast Cancer Version 1.2023
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 2.2023
Colon Cancer Version 3.2022
Hepatobiliary Cancers Version 5.2022
Kidney Cancer Version 4.2023
Pediatric Hodgkin Lymphoma Version 1.2023
Primary Cutaneous Lymphomas Version 1.2023
Rectal Cancer Version 4.2022
Small Bowel Adenocarcinoma Version 1.2023
T-Cell Lymphomas Version 1.2023
Testicular Cancer Version 1.2023
NCCN Guidelines with Evidence Blocks - Acute Myeloid Leukemia Version 3.2022
NCCN Guidelines with Evidence Blocks - Anal Carcinoma Version 1.2023
NCCN Guidelines with Evidence Blocks - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 2.2023
NCCN Guidelines with Evidence Blocks - Hepatobiliary Cancers Version 5.2022
NCCN Guidelines with Evidence Blocks - Pediatric Hodgkin Lymphoma Version 1.2023
NCCN Guidelines with Evidence Blocks - Primary Cutaneous Lymphomas Version 1.2023
NCCN Guidelines with Evidence Blocks - Small Bowel Adenocarcinoma Version 1.2023
NCCN Guidelines with Evidence Blocks - T-Cell Lymphomas Version 1.2023
NCCN Guidelines with Evidence Blocks - Testicular Cancer Version 1.2023
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 2.2023
Prostate Cancer Early Detection Version 1.2023
Antiemesis Version 1.2023
Cancer-Related Fatigue Version 2.2023
Hematopoietic Cell Transplantation Version 3.2022
Palliative Care Version 1.2023
Smoking Cessation Version 3.2022
Adolescent and Young Adult (AYA) Oncology Version 3.2023